Navigation Links
Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Date:11/24/2009

ain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner or commercialize lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.


Contact: Arena Pharmaceuticals, Inc.
Jack Lief
President and CEO

Cindy McGee
Manager, IR and Corporate Communications
858.453.7200, ext. 1479

Media Contact: Russo Partners
David Schull, President
'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Veracyte, Inc. (NASDAQ: ... Anderson , president and chief executive officer, will present ... September 16, 2015 at 10:30 a.m. ET in ... The live audio webcast and subsequent replay may be ... will be available shortly after conclusion of the presentation ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical imaging processing ... sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ONYX ZEUS ... decisions with simultaneous access to high precision medical images and electronic health records. ...
(Date:9/2/2015)... ... 2015 , ... Genedata, a leading provider of advanced software ... ® version 13.0 at ELRIG Drug Discovery 2015. This latest version of the ... new capabilities. Screener now supports High Throughput Flow Cytometry (HT-Flow) and Drug Metabolism ...
(Date:9/1/2015)...  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... Global Investment Conference sponsored by H.C. Wainwright ... St. Regis Hotel in New York, NY ... Chief Executive Officer, will provide an overview of the ...
Breaking Biology Technology:Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced ... granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, ... (LEMS). 3,4-DAP has previously received orphan drug designation ... Committee for Medicinal Products for Human Use of the ...
... , ... rapidly growing,orthobiologics company, was named Europe,s fastest growing,Biotech/Pharmaceutical/Medical Technology/Equipment company ... East and Africa). , This annual ... ApaTech has achieved a rate of 8,318% over this period. ...
... , , ... to market Oralair(R) in both adults and children,through a ... been marketed, was the reference Member state. , ... Belgium, Bulgaria, Cyprus, the,Czech Republic, Estonia, France, Germany, Greece, ...
Cached Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3
(Date:8/31/2015)... Growing need for data security coupled with ... drive India biometrics market   ... India Biometrics Market Forecast & Opportunities, 2020 ", biometrics market ... at a CAGR of over 35% during 2015 - 2020. ... use of biometric technology in the government sector. Ongoing government ...
(Date:8/26/2015)... PUNE, India , August 26, 2015 ... (Two, Three, Four, and Five Factor), Application (Travel & ... and Geography - Global Forecast to 2020", published by ... 9.60 Billion by 2020, growing at a CAGR of ... 71 Tables and 82 F igures spread through ...
(Date:8/24/2015)... VIEW, Calif. , Aug. 24, 2015  Based on ... Sullivan recognizes DERMALOG with the 2015 African Biometrics Company of ... and has achieved substantial commercial success in Africa ... Nigeria , where it has implemented one of the ... 23 banks as well as the Central Bank of ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6
... introduced ,Delicious, a new muscadine grape cultivar. ,Delicious, ripens ... fruit features exceptional taste and texture with an edible ... the potential for wine production. The name ,Delicious, was ... sampled the fruit., According to Dr. Dennis J. Gray, ...
... placed increasing demands on available water resources. In 2007, ... where the population approached two million people. The dual ... features frequent severe drought conditions has created an urgent ... meet resident and visitor demand., Las Vegas operates on ...
... vital component of good health. Like plants that thrive in ... case for the production of vitamin D. In the past ... sun exposure. From fear of the potential dangers of UV ... work and recreational environments centered on virtual reality, we are ...
Cached Biology News:Keeping golf courses green when fresh water is limited 2Keeping golf courses green when fresh water is limited 3The sunlight solution for better health 2The sunlight solution for better health 3
... The Bio-Stack is compatible with ... systems. Speed, ease of use and ... routine microplate process. When used with ... reagent dispenser, the Bio-Stacks small footprint ...
... use of small interfering RNA (siRNA) molecules ... interference,(RNAi) pathway have generated tremendous interest in ... for experimental use can be,synthesized in vitro, ... into the target cells in vitro or ...
... S&S Custom Array Service enables scientists who have ... to have FAST Slides printed with proteins from ... Processing of the arrays is performed by the ... S&S to discuss your needs with an expert ...
... demands of the routine trace metal analytical ... robust and simple to use instrumentation. The ... most challenging sample matrices found in the ... the toughest analytical challenges found in the ...
Biology Products: